Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients

by Vandana Singh, Benzinga Editor
September 16, 2021 10:10 AM | 1 min read |
  • The FDA has signed off Intellia Therapeutics Inc's NTLA investigational new drug (IND) application for NTLA-5001.
  • Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate.
  • NTLA-5001 is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms' Tumor (WT1) antigen for the treatment of all genetic subtypes of acute myeloid leukemia (AML).
  • Intellia plans to initiate patient screening by the end of 2021 for the Phase 1/2a study evaluating NTLA-5001 in adults with persistent or recurrent AML who have previously received first-line therapy.
  • The Phase 1/2a study will evaluate the safety, tolerability, cell kinetics, and anti-tumor activity of a single dose of NTLA-5001.
  • The study will contain a dose escalation and expansion phase, with up to 54 participants. 
  • Price Action: NTLA shares are up 1.44% at $152.73 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralacute myeloid leukemiaBriefscancergene therapyPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!